The combined diagnostic value of 5-hmC and PRAME immunohistochemistry in melanocytic neoplasms

The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be...

Full description

Saved in:
Bibliographic Details
Published inPathology, research and practice Vol. 270; p. 155993
Main Authors Yu, Yanhong, Hosseini, Niloufar, Dodington, David, Wood, Kimberly, Ghazarian, Danny, Kamil, Zaid Saeed
Format Journal Article
LanguageEnglish
Published Germany Elsevier GmbH 01.06.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms.
AbstractList The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms.
The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms.The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms.
ArticleNumber 155993
Author Kamil, Zaid Saeed
Wood, Kimberly
Ghazarian, Danny
Yu, Yanhong
Hosseini, Niloufar
Dodington, David
Author_xml – sequence: 1
  givenname: Yanhong
  surname: Yu
  fullname: Yu, Yanhong
  email: yanhong.yu@mail.utoronto.ca
  organization: University of Toronto, Toronto, ON, Canada
– sequence: 2
  givenname: Niloufar
  surname: Hosseini
  fullname: Hosseini, Niloufar
  organization: The Ottawa Hospital, Ottawa, ON, Canada
– sequence: 3
  givenname: David
  surname: Dodington
  fullname: Dodington, David
  organization: University of Toronto, Toronto, ON, Canada
– sequence: 4
  givenname: Kimberly
  surname: Wood
  fullname: Wood, Kimberly
  organization: University of Saskatchewan, Regina Pasqua Hospital, Regina, SK, Canada
– sequence: 5
  givenname: Danny
  surname: Ghazarian
  fullname: Ghazarian, Danny
  organization: University of Toronto, Toronto, ON, Canada
– sequence: 6
  givenname: Zaid Saeed
  surname: Kamil
  fullname: Kamil, Zaid Saeed
  organization: University of Toronto, Toronto, ON, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40328178$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtrGzEUhUVJqR_tD-gmaNnNOHqMZsZ0FYzTBhIagrut0Eh3apmRNJVmDP73kXHSZVYHLt-5nHMW6MoHDwh9pWRFCa1uDqshDitGmFhRIdZr_gHNaUWbglScXqE54WVZEM6bGVqkdCCE1KSkn9CsJJw1tG7m6M9uD1gH11oPBhur_vqQRqvxUfUT4NBhUezdBitv8NPz7eMWW-cmH_Y2jUHvwWWNJ2w9dtArH_TpbPYQhl4llz6jj53qE3x51SX6fbfdbX4WD79-3G9uHwrNST0WFW87Y2qjOgHQEACoOaGKlg2YThtdG2DMiLZat4LpygjRsbJudMd4a0Ruu0TfLn-HGP5NkEaZg2nocyQIU5KcEUqpqNcso9ev6NQ6MHKI1ql4km-bZIBeAB1DShG6_wgl8ry7POTLIM-7y8vu2fP94oFc8mghyqQteA3GRtCjNMG-434BLsKLXQ
Cites_doi 10.1111/cup.14245
10.1097/PAS.0000000000001393
10.18632/oncotarget.6062
10.1038/modpathol.2013.224
10.1016/j.jid.2016.07.015
10.1097/PAS.0000000000002032
10.1111/cup.13412
10.1186/s13000-022-01218-3
10.1111/cup.14290
10.1111/cup.14212
10.1097/PAS.0000000000001134
10.1097/CMR.0000000000000315
10.1002/mc.22638
10.1038/bjc.2016.187
10.1111/cup.14226
10.1016/j.humpath.2021.11.002
10.1016/j.jdermsci.2013.09.008
10.3390/jcm13061554
10.1111/cup.14267
10.1038/sj.bjc.6605880
10.1111/cup.13958
10.1111/cup.12564
10.1016/j.humpath.2021.12.008
10.1016/j.cell.2012.07.033
10.18632/oncotarget.316
10.1038/modpathol.2014.99
10.1016/j.labinv.2025.104123
10.1016/j.pathol.2022.05.012
10.1016/S1074-7613(00)80426-4
10.1038/modpathol.2016.159
10.1111/cup.12880
10.1371/journal.pone.0146302
10.3390/cancers13153864
ContentType Journal Article
Copyright 2025
Crown Copyright © 2025. Published by Elsevier GmbH. All rights reserved.
Copyright © 2025. Published by Elsevier GmbH.
Copyright_xml – notice: 2025
– notice: Crown Copyright © 2025. Published by Elsevier GmbH. All rights reserved.
– notice: Copyright © 2025. Published by Elsevier GmbH.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.prp.2025.155993
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1618-0631
ExternalDocumentID 40328178
10_1016_j_prp_2025_155993
S0344033825001852
Genre Journal Article
GroupedDBID ---
--K
--M
.55
.GJ
.~1
0R~
123
1B1
1~.
1~5
29O
3O-
4.4
457
4CK
4G.
53G
5RE
5VS
7-5
71M
7X7
88E
88I
8AF
8FE
8FH
8FI
8FJ
8G5
8P~
8R4
8R5
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AAKPP
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABGSF
ABLJU
ABMAC
ABMZM
ABUDA
ABUWG
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACGOD
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADKUU
ADMUD
ADNMO
ADUVX
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AFJKZ
AFKRA
AFPUW
AFTJW
AGCQF
AGHFR
AGQPQ
AGRDE
AGRNS
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AKBMS
AKRWK
AKYEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
AZQEC
BBNVY
BCR
BCU
BEC
BENPR
BHPHI
BKOJK
BLC
BLXMC
BNPGV
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
DU5
DWQXO
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
LK8
M1P
M2O
M2P
M2Q
M41
M7P
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PADUT
PC.
PEA
PHGZM
PHGZT
PQQKQ
PRG
PROAC
PSQYO
Q2X
Q38
R2-
RIG
ROL
RPZ
S0X
SDF
SDG
SES
SEW
SJFOW
SSU
SSZ
T5I
T5J
T5K
UDS
UKHRP
X7M
ZGI
ZXP
~G-
AAYXX
ACIEU
CITATION
AFXIZ
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
PJZUB
PPXIY
PQGLB
7X8
ID FETCH-LOGICAL-c307t-63bfdd7daf5ee80eee7301a148edfcdc7de22d5b69b52c6d55f2478cf23bd5063
IEDL.DBID .~1
ISSN 0344-0338
1618-0631
IngestDate Fri Jul 11 18:20:19 EDT 2025
Mon Jul 21 05:50:24 EDT 2025
Tue Jul 01 04:42:10 EDT 2025
Sat Jun 14 16:51:21 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Immunohistochemistry
PReferentially expressed Antigen in MElanoma
5-hydroxymethylcytosine
Melanoma
Nevus
Language English
License Crown Copyright © 2025. Published by Elsevier GmbH. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c307t-63bfdd7daf5ee80eee7301a148edfcdc7de22d5b69b52c6d55f2478cf23bd5063
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 40328178
PQID 3201115792
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3201115792
pubmed_primary_40328178
crossref_primary_10_1016_j_prp_2025_155993
elsevier_sciencedirect_doi_10_1016_j_prp_2025_155993
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-06-01
PublicationDateYYYYMMDD 2025-06-01
PublicationDate_xml – month: 06
  year: 2025
  text: 2025-06-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Pathology, research and practice
PublicationTitleAlternate Pathol Res Pract
PublicationYear 2025
Publisher Elsevier GmbH
Publisher_xml – name: Elsevier GmbH
References Gassenmaier (bib27) Jul 31 2021; 13
Kim (bib24) Apr 28 2022; 17
Larson (bib12) Jul 2014; 27
Fang (bib28) Feb 28 2025; 105
Lee (bib15) Mar 2017; 44
Rothrock (bib20) Oct 2022; 49
Parra, Linos, Li, Yan (bib23) Jul 2022; 49
Ricci (bib26) May 01 2023; 47
Rodić, Zampella, Sharma, Burns, Taube (bib8) Nov 2015; 42
Rawson (bib17) Dec 2022; 54
Koh, Lau, Scapa, Cassarino (bib22) Aug 2022; 49
Lezcano, Pulitzer, Moy, Hollmann, Jungbluth, Busam (bib4) Apr 2020; 44
Uchiyama (bib9) Feb 2014; 73
Benešová (bib33) Aug 2017; 56
Lezcano, Jungbluth, Nehal, Hollmann, Busam (bib2) Nov 2018; 42
Lee (bib13) Feb 2015; 28
Haffner (bib11) Aug 2011; 2
Ikeda (bib1) Feb 1997; 6
Lohman, Steen, Grekin, North (bib6) Jul 2021; 48
O'Connor, Dai, Fraga (bib21) Sep 2022; 49
Saldanha (bib16) Jan 2017; 30
Kaczorowski, Lasota, Dudek, Małkiewicz, Miettinen, Hałoń (bib29) Mar 08 2024; 13
Pavlova, Fraitag, Hohl (bib10) Dec 2016; 136
Siref, Huynh, Balzer, Frishberg, Essner, Shon (bib14) Apr 2019; 46
Munari (bib34) 2016; 11
Lian (bib7) Sep 14 2012; 150
Olds, Utz, Abrams, Terrano, Mehregan (bib5) Jun 2022; 49
Lee (bib19) Nov 10 2015; 6
Almstrup (bib30) Oct 12 2010; 103
Hu (bib25) Feb 2022; 120
Orsatti (bib31) Sep 2022; 237
Fattori, de la Fouchardière, Cribier, Mitcov (bib3) Mar 2022; 121
Nettersheim (bib32) Aug 09 2016; 115
Micevic, Theodosakis, Taube, Bosenberg, Rodić (bib18) Apr 2017; 27
Saldanha (10.1016/j.prp.2025.155993_bib16) 2017; 30
Haffner (10.1016/j.prp.2025.155993_bib11) 2011; 2
Olds (10.1016/j.prp.2025.155993_bib5) 2022; 49
Gassenmaier (10.1016/j.prp.2025.155993_bib27) 2021; 13
Koh (10.1016/j.prp.2025.155993_bib22) 2022; 49
Hu (10.1016/j.prp.2025.155993_bib25) 2022; 120
Rawson (10.1016/j.prp.2025.155993_bib17) 2022; 54
Nettersheim (10.1016/j.prp.2025.155993_bib32) 2016; 115
Micevic (10.1016/j.prp.2025.155993_bib18) 2017; 27
Lezcano (10.1016/j.prp.2025.155993_bib4) 2020; 44
Lee (10.1016/j.prp.2025.155993_bib15) 2017; 44
Lian (10.1016/j.prp.2025.155993_bib7) 2012; 150
Fang (10.1016/j.prp.2025.155993_bib28) 2025; 105
Lezcano (10.1016/j.prp.2025.155993_bib2) 2018; 42
Rodić (10.1016/j.prp.2025.155993_bib8) 2015; 42
O'Connor (10.1016/j.prp.2025.155993_bib21) 2022; 49
Benešová (10.1016/j.prp.2025.155993_bib33) 2017; 56
Fattori (10.1016/j.prp.2025.155993_bib3) 2022; 121
Ikeda (10.1016/j.prp.2025.155993_bib1) 1997; 6
Pavlova (10.1016/j.prp.2025.155993_bib10) 2016; 136
Orsatti (10.1016/j.prp.2025.155993_bib31) 2022; 237
Lohman (10.1016/j.prp.2025.155993_bib6) 2021; 48
Munari (10.1016/j.prp.2025.155993_bib34) 2016; 11
Lee (10.1016/j.prp.2025.155993_bib19) 2015; 6
Larson (10.1016/j.prp.2025.155993_bib12) 2014; 27
Rothrock (10.1016/j.prp.2025.155993_bib20) 2022; 49
Ricci (10.1016/j.prp.2025.155993_bib26) 2023; 47
Uchiyama (10.1016/j.prp.2025.155993_bib9) 2014; 73
Siref (10.1016/j.prp.2025.155993_bib14) 2019; 46
Kim (10.1016/j.prp.2025.155993_bib24) 2022; 17
Kaczorowski (10.1016/j.prp.2025.155993_bib29) 2024; 13
Almstrup (10.1016/j.prp.2025.155993_bib30) 2010; 103
Lee (10.1016/j.prp.2025.155993_bib13) 2015; 28
Parra (10.1016/j.prp.2025.155993_bib23) 2022; 49
References_xml – volume: 28
  start-page: 218
  year: Feb 2015
  end-page: 229
  ident: bib13
  article-title: 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies
  publication-title: Mod. Pathol.
– volume: 237
  year: Sep 2022
  ident: bib31
  article-title: SOX2 and PRAME in the reprogramming of seminoma cells
  publication-title: Pathol. Res Pr.
– volume: 13
  year: Mar 08 2024
  ident: bib29
  article-title: Expression of immunotherapy target PRAME in cancer correlates with histone H3 acetylation and is unrelated to expression of methylating (DMNT3A/3B) and demethylating (TET1) enzymes
  publication-title: J. Clin. Med.
– volume: 120
  start-page: 9
  year: Feb 2022
  end-page: 17
  ident: bib25
  article-title: Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi
  publication-title: Hum. Pathol.
– volume: 49
  start-page: 709
  year: Aug 2022
  end-page: 716
  ident: bib22
  article-title: PRAME immunohistochemistry of spitzoid neoplasms
  publication-title: J. Cutan. Pathol.
– volume: 42
  start-page: 807
  year: Nov 2015
  end-page: 814
  ident: bib8
  article-title: Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations
  publication-title: J. Cutan. Pathol.
– volume: 44
  start-page: 249
  year: Mar 2017
  end-page: 255
  ident: bib15
  article-title: 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms
  publication-title: J. Cutan. Pathol.
– volume: 30
  start-page: 60
  year: Jan 2017
  end-page: 68
  ident: bib16
  article-title: 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma
  publication-title: Mod. Pathol.
– volume: 105
  year: Feb 28 2025
  ident: bib28
  article-title: PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation
  publication-title: Lab Invest
– volume: 56
  start-page: 1837
  year: Aug 2017
  end-page: 1850
  ident: bib33
  article-title: Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation
  publication-title: Mol. Carcinog.
– volume: 6
  start-page: 199
  year: Feb 1997
  end-page: 208
  ident: bib1
  article-title: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
  publication-title: Immunity
– volume: 49
  start-page: 780
  year: Sep 2022
  end-page: 786
  ident: bib21
  article-title: PRAME immunohistochemistry for melanoma diagnosis: a STARD-compliant diagnostic accuracy study, (in eng)
  publication-title: J. Cutan. Pathol.
– volume: 48
  start-page: 856
  year: Jul 2021
  end-page: 862
  ident: bib6
  article-title: The utility of PRAME staining in identifying malignant transformation of melanocytic nevi
  publication-title: J. Cutan. Pathol.
– volume: 11
  year: 2016
  ident: bib34
  article-title: Global 5-hydroxymethylcytosine levels are profoundly reduced in multiple genitourinary malignancies
  publication-title: PLoS One
– volume: 46
  start-page: 261
  year: Apr 2019
  end-page: 266
  ident: bib14
  article-title: Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: an effective first-line test for the workup of sentinel lymph node specimen
  publication-title: J. Cutan. Pathol.
– volume: 121
  start-page: 19
  year: Mar 2022
  end-page: 28
  ident: bib3
  article-title: Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation
  publication-title: Hum. Pathol.
– volume: 136
  start-page: 2453
  year: Dec 2016
  end-page: 2461
  ident: bib10
  article-title: 5-Hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma
  publication-title: J. Invest Dermatol.
– volume: 115
  start-page: 454
  year: Aug 09 2016
  end-page: 464
  ident: bib32
  article-title: The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas
  publication-title: Br. J. Cancer
– volume: 6
  start-page: 37995
  year: Nov 10 2015
  end-page: 38004
  ident: bib19
  article-title: Loss of the epigenetic mark, 5-hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma
  publication-title: Oncotarget
– volume: 17
  start-page: 41
  year: Apr 28 2022
  ident: bib24
  article-title: Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit
  publication-title: Diagn. Pathol.
– volume: 54
  start-page: 863
  year: Dec 2022
  end-page: 873
  ident: bib17
  article-title: Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics
  publication-title: Pathology
– volume: 103
  start-page: 1269
  year: Oct 12 2010
  end-page: 1276
  ident: bib30
  article-title: Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells
  publication-title: Br. J. Cancer
– volume: 44
  start-page: 503
  year: Apr 2020
  end-page: 508
  ident: bib4
  article-title: Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma
  publication-title: Am. J. Surg. Pathol.
– volume: 150
  start-page: 1135
  year: Sep 14 2012
  end-page: 1146
  ident: bib7
  article-title: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma
  publication-title: Cell
– volume: 27
  start-page: 936
  year: Jul 2014
  end-page: 944
  ident: bib12
  article-title: Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors
  publication-title: Mod. Pathol.
– volume: 49
  start-page: 510
  year: Jun 2022
  end-page: 514
  ident: bib5
  article-title: Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions
  publication-title: J. Cutan. Pathol.
– volume: 49
  start-page: 859
  year: Oct 2022
  end-page: 867
  ident: bib20
  article-title: Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions
  publication-title: J. Cutan. Pathol.
– volume: 42
  start-page: 1456
  year: Nov 2018
  end-page: 1465
  ident: bib2
  article-title: PRAME expression in melanocytic tumors
  publication-title: Am. J. Surg. Pathol.
– volume: 49
  start-page: 610
  year: Jul 2022
  end-page: 617
  ident: bib23
  article-title: PRAME expression in melanocytic lesions of the nail
  publication-title: J. Cutan. Pathol.
– volume: 13
  year: Jul 31 2021
  ident: bib27
  article-title: Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas
  publication-title: Cancers (Basel)
– volume: 2
  start-page: 627
  year: Aug 2011
  end-page: 637
  ident: bib11
  article-title: Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers
  publication-title: Oncotarget
– volume: 73
  start-page: 161
  year: Feb 2014
  end-page: 163
  ident: bib9
  article-title: 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi
  publication-title: J. Dermatol. Sci.
– volume: 27
  start-page: 85
  year: Apr 2017
  end-page: 96
  ident: bib18
  article-title: Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas
  publication-title: Melanoma Res
– volume: 47
  start-page: 599
  year: May 01 2023
  end-page: 610
  ident: bib26
  article-title: PRAME expression in mucosal melanoma of the head and neck region
  publication-title: Am. J. Surg. Pathol.
– volume: 49
  start-page: 709
  issue: 8
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib22
  article-title: PRAME immunohistochemistry of spitzoid neoplasms
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.14245
– volume: 44
  start-page: 503
  issue: 4
  year: 2020
  ident: 10.1016/j.prp.2025.155993_bib4
  article-title: Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/PAS.0000000000001393
– volume: 6
  start-page: 37995
  issue: 35
  year: 2015
  ident: 10.1016/j.prp.2025.155993_bib19
  article-title: Loss of the epigenetic mark, 5-hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6062
– volume: 27
  start-page: 936
  issue: 7
  year: 2014
  ident: 10.1016/j.prp.2025.155993_bib12
  article-title: Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2013.224
– volume: 136
  start-page: 2453
  issue: 12
  year: 2016
  ident: 10.1016/j.prp.2025.155993_bib10
  article-title: 5-Hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma
  publication-title: J. Invest Dermatol.
  doi: 10.1016/j.jid.2016.07.015
– volume: 47
  start-page: 599
  issue: 5
  year: 2023
  ident: 10.1016/j.prp.2025.155993_bib26
  article-title: PRAME expression in mucosal melanoma of the head and neck region
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/PAS.0000000000002032
– volume: 46
  start-page: 261
  issue: 4
  year: 2019
  ident: 10.1016/j.prp.2025.155993_bib14
  article-title: Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: an effective first-line test for the workup of sentinel lymph node specimen
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.13412
– volume: 17
  start-page: 41
  issue: 1
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib24
  article-title: Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit
  publication-title: Diagn. Pathol.
  doi: 10.1186/s13000-022-01218-3
– volume: 49
  start-page: 859
  issue: 10
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib20
  article-title: Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.14290
– volume: 49
  start-page: 510
  issue: 6
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib5
  article-title: Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.14212
– volume: 42
  start-page: 1456
  issue: 11
  year: 2018
  ident: 10.1016/j.prp.2025.155993_bib2
  article-title: PRAME expression in melanocytic tumors
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/PAS.0000000000001134
– volume: 27
  start-page: 85
  issue: 2
  year: 2017
  ident: 10.1016/j.prp.2025.155993_bib18
  article-title: Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas
  publication-title: Melanoma Res
  doi: 10.1097/CMR.0000000000000315
– volume: 56
  start-page: 1837
  issue: 8
  year: 2017
  ident: 10.1016/j.prp.2025.155993_bib33
  article-title: Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation
  publication-title: Mol. Carcinog.
  doi: 10.1002/mc.22638
– volume: 115
  start-page: 454
  issue: 4
  year: 2016
  ident: 10.1016/j.prp.2025.155993_bib32
  article-title: The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2016.187
– volume: 49
  start-page: 610
  issue: 7
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib23
  article-title: PRAME expression in melanocytic lesions of the nail
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.14226
– volume: 120
  start-page: 9
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib25
  article-title: Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2021.11.002
– volume: 73
  start-page: 161
  issue: 2
  year: 2014
  ident: 10.1016/j.prp.2025.155993_bib9
  article-title: 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi
  publication-title: J. Dermatol. Sci.
  doi: 10.1016/j.jdermsci.2013.09.008
– volume: 13
  issue: 6
  year: 2024
  ident: 10.1016/j.prp.2025.155993_bib29
  article-title: Expression of immunotherapy target PRAME in cancer correlates with histone H3 acetylation and is unrelated to expression of methylating (DMNT3A/3B) and demethylating (TET1) enzymes
  publication-title: J. Clin. Med.
  doi: 10.3390/jcm13061554
– volume: 49
  start-page: 780
  issue: 9
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib21
  article-title: PRAME immunohistochemistry for melanoma diagnosis: a STARD-compliant diagnostic accuracy study, (in eng)
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.14267
– volume: 103
  start-page: 1269
  issue: 8
  year: 2010
  ident: 10.1016/j.prp.2025.155993_bib30
  article-title: Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6605880
– volume: 48
  start-page: 856
  issue: 7
  year: 2021
  ident: 10.1016/j.prp.2025.155993_bib6
  article-title: The utility of PRAME staining in identifying malignant transformation of melanocytic nevi
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.13958
– volume: 42
  start-page: 807
  issue: 11
  year: 2015
  ident: 10.1016/j.prp.2025.155993_bib8
  article-title: Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.12564
– volume: 121
  start-page: 19
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib3
  article-title: Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2021.12.008
– volume: 150
  start-page: 1135
  issue: 6
  year: 2012
  ident: 10.1016/j.prp.2025.155993_bib7
  article-title: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma
  publication-title: Cell
  doi: 10.1016/j.cell.2012.07.033
– volume: 2
  start-page: 627
  issue: 8
  year: 2011
  ident: 10.1016/j.prp.2025.155993_bib11
  article-title: Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.316
– volume: 28
  start-page: 218
  issue: 2
  year: 2015
  ident: 10.1016/j.prp.2025.155993_bib13
  article-title: 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2014.99
– volume: 105
  issue: 5
  year: 2025
  ident: 10.1016/j.prp.2025.155993_bib28
  article-title: PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation
  publication-title: Lab Invest
  doi: 10.1016/j.labinv.2025.104123
– volume: 54
  start-page: 863
  issue: 7
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib17
  article-title: Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics
  publication-title: Pathology
  doi: 10.1016/j.pathol.2022.05.012
– volume: 6
  start-page: 199
  issue: 2
  year: 1997
  ident: 10.1016/j.prp.2025.155993_bib1
  article-title: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80426-4
– volume: 30
  start-page: 60
  issue: 1
  year: 2017
  ident: 10.1016/j.prp.2025.155993_bib16
  article-title: 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2016.159
– volume: 44
  start-page: 249
  issue: 3
  year: 2017
  ident: 10.1016/j.prp.2025.155993_bib15
  article-title: 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.12880
– volume: 11
  issue: 1
  year: 2016
  ident: 10.1016/j.prp.2025.155993_bib34
  article-title: Global 5-hydroxymethylcytosine levels are profoundly reduced in multiple genitourinary malignancies
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0146302
– volume: 237
  year: 2022
  ident: 10.1016/j.prp.2025.155993_bib31
  article-title: SOX2 and PRAME in the reprogramming of seminoma cells
  publication-title: Pathol. Res Pr.
– volume: 13
  issue: 15
  year: 2021
  ident: 10.1016/j.prp.2025.155993_bib27
  article-title: Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13153864
SSID ssj0007041
Score 2.3940105
Snippet The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology....
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 155993
SubjectTerms 5-hydroxymethylcytosine
5-Methylcytosine - analogs & derivatives
Adolescent
Adult
Aged
Antigens, Neoplasm - analysis
Antigens, Neoplasm - metabolism
Biomarkers, Tumor - analysis
Diagnosis, Differential
Dysplastic Nevus Syndrome - diagnosis
Dysplastic Nevus Syndrome - metabolism
Dysplastic Nevus Syndrome - pathology
Female
Humans
Immunohistochemistry
Male
Melanoma
Melanoma - diagnosis
Melanoma - metabolism
Melanoma - pathology
Middle Aged
Nevus
Nevus, Epithelioid and Spindle Cell - diagnosis
Nevus, Epithelioid and Spindle Cell - metabolism
Nevus, Epithelioid and Spindle Cell - pathology
PReferentially expressed Antigen in MElanoma
Retrospective Studies
Skin Neoplasms - diagnosis
Skin Neoplasms - metabolism
Skin Neoplasms - pathology
Young Adult
Title The combined diagnostic value of 5-hmC and PRAME immunohistochemistry in melanocytic neoplasms
URI https://dx.doi.org/10.1016/j.prp.2025.155993
https://www.ncbi.nlm.nih.gov/pubmed/40328178
https://www.proquest.com/docview/3201115792
Volume 270
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwEA9DQXwRv50fI4JPQrcuTZr2cYyNqWyIOtiTpc0lOHHtcNuDL_7t5vqh-DAffGxIaPu75O7C_e6OkKskASZl6DtBwpWDgSEnDLjBrqlKGc6U8TDfeTjyB2N-OxGTGulWuTBIqyx1f6HTc21djrRKNFvz6bT1iMXqXHvDskbcxRRgzGDnEnd58_OH5iHdvHslTnZwdhXZzDle87xkJRNNDM6F3jrbtM73zG1Qf5fslM4j7RTft0dqOt0nW8MyPH5Anq3Qqf0Te9vVQKFg0dm5FEt6a5oZKpyXWZfGKdD7h86wR6eYHpLlRYdV1fqNTlM6029xmqkPXJwiyTxezBaHZNzvPXUHTtlAwVH26C4d30sMgITYCK0DV2uN5zm2NyANRoGSoBkDkfhhIpjyQQjDuAyUYV4CwjovR2QjzVJ9QmjY1gqkNe-xAq58E0phF4A2wBRTblAn1xV00byokxFVBLJXOzKPEOeowLlOeAVu9EvYkdXjfy27rAQRWUAwshFbCFaLyEM3pi1kyOrkuJDQ91dwrBjYlsHp_156RrbxqWCHnZON5ftKX1g_ZJk08o3WIJudm7vB6Atg8N1c
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5RKrW9VH13-6Cu1F4qhc06dpwcekA8tBQWVS1InGoSj60uYrOr7qKKS_8Uf5CZPEAc6AGJqxMn1ufRPDTfzAB8KkuUxuRplJXKRZwYivJMBZ6a6lxQ0oWE651He-nwQH071IdLcN7VwjCtstX9jU6vtXW70m_R7M_G4_5PblYXU4RFRjzmEuCWWbnjz_5S3Db_ur1Bl_xZyq3N_fVh1I4WiBwJ9SJKkzIgGiyC9j6Lvfcs6QXFBh6DQ2fQS4m6TPNSS5ei1kEqk7kgkxI1mXX67j24r0hd8NiE1X9XvBIT1-My-XQRH69LpdakslndI1PqVc4G5slNxvAmZ7c2eltP4HHrrYq1BpCnsOSrZ_Bg1Objn8MvkjJB0FF47VFgQ9ujdwX3EPdiGoSOfk_WRVGh-P5jbbQpxlyPMq27HLtu1pwYV2LiT4pq6s54c8Ws9mI-mb-AgzuB9SUsV9PKvwaRD7xDQ_5E4VC5NORG0wb0AaWTLs568KWDzs6axhy2Y6wd08rMMs62wbkHqgPXXpMuS4bjf9s-dhdhCRBOpRQEwencJuw3DbTJZQ9eNTd0eQrFLQoHJntzu59-gIfD_dGu3d3e23kLj_hJQ017B8uLP6f-PTlBi3KlFjoBR3ct5RcKPxt5
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+combined+diagnostic+value+of+5-hmC+and+PRAME+immunohistochemistry+in+melanocytic+neoplasms&rft.jtitle=Pathology%2C+research+and+practice&rft.au=Yu%2C+Yanhong&rft.au=Hosseini%2C+Niloufar&rft.au=Dodington%2C+David&rft.au=Wood%2C+Kimberly&rft.date=2025-06-01&rft.issn=1618-0631&rft.eissn=1618-0631&rft.volume=270&rft.spage=155993&rft_id=info:doi/10.1016%2Fj.prp.2025.155993&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-0338&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-0338&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-0338&client=summon